Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma Journal Article


Authors: Mier-Hicks, A.; Raj, M.; Do, R. K.; Yu, K. H.; Lowery, M. A.; Varghese, A.; O'Reilly, E. M.
Article Title: Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma
Abstract: In a cohort analysis evaluating patients with pancreatic adenocarcinoma who presented with or developed visceral thrombosis, including portal, mesenteric, and splenic vein, as well as thrombi in renal or gonadal veins, among the 95 patients analyzed, 154 visceral thrombosis events (VTE) occurred. VTE frequently presented as an incidental finding on routine abdominal imaging, with the most common location being portal vein, followed by mesenteric and splenic vein. Patients who received systemic anticoagulation had a low bleeding complication rate. Background: Visceral or splanchnic thrombosis is defined as thrombi within the hepatoportal venous system, including portal (PV), mesenteric (MV), and splenic vein (SV), as well as thrombi in renal or gonadal veins. There are limited data to evaluate the prognostic significance, incidence, and clinical management of visceral thromboses in patients with pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We conducted an analysis of 95 patients treated at Memorial Sloan Kettering Cancer Center with PDAC who had a visceral thrombosis. Results: A total of 153 visceral thromboses (VsT) were identified in 95 patients (n = 51, 54% woman). A total of 36 patients (37%) had locally advanced disease, and n = 59 (62%) had metastatic disease. Systemic therapies received included FOLFIRINOX (n = 57, 60%) and GC/PTX (n = 27, 28%). All VsT events were incidentally detected. Overall survival of cohort was 12.3 months (range, 10.2-14.4 months). Visceral thrombosis incidence in the cohort was as follows: portal vein (PV) (45%), MV (26%), SV (17%), and gonadal veins (8%). Time to develop first VsT was 4.3 months (range, 3-5.6 months), and time to death from VsT development was 1.87 months (range, 0.8-2.8 months). Forty-five patients (47%) developed a second VsT. Sixty percent had a Khorana risk score of > 3. Thirty-nine patients (41%) were treated with short-term anticoagulation (AC) (< 1 month) (low-molecular-weight heparin, n = 34). Forty-five patients (47%) were treated with long-term AC (> 1 month) (low-molecular-weight heparin, n = 32; 23 were transitioned to an oral anticoagulant). Twenty-two patients (23%) were not treated with AC. Eight patients (8%) had a bleeding complication from AC. Portal vein thrombosis had the shortest overall survival at 3.6 months (range, 2.3-4.8 months). Conclusion: In PDAC, VsT can frequently present as an incidental finding on routine abdominal imaging. The most common location is PV, followed by MV and SV. We observed that AC is underutilized in this setting despite a low bleeding complication rate. PV was associated with the least overall survival of the VsT. Future large prospective studies should explore the role of AC and value in this setting. © 2018 Elsevier Inc.
Keywords: portal vein thrombosis; mesenteric vein thrombosis; splanchnic vein thrombosis; splenic vein thrombosis; antithrombotic treatment
Journal Title: Clinical Colorectal Cancer
Volume: 17
Issue: 2
ISSN: 1533-0028
Publisher: Elsevier Inc.  
Date Published: 2018-06-01
Start Page: 121
End Page: 128
Language: English
DOI: 10.1016/j.clcc.2018.01.008
PROVIDER: scopus
PUBMED: 29477452
DOI/URL:
Notes: Article -- Export Date: 2 July 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Maeve Aine Lowery
    98 Lowery
  2. Kinh Gian Do
    116 Do
  3. Eileen O'Reilly
    324 O'Reilly
  4. Micheal Raj
    2 Raj